Enovis Corporation Reports Strong Q1 2025 Growth

Enovis Corporation ( (ENOV) ) has released its Q1 earnings. Here is a breakdown of the information Enovis Corporation presented to its investors.

Enovis Corporation is a medical technology company focused on developing innovative solutions to improve patient outcomes and streamline workflows, primarily in the orthopedic sector. The company is known for its commitment to continuous improvement and global innovation.

In the first quarter of 2025, Enovis Corporation reported an 8% increase in net sales, reaching $559 million, with significant growth in its Reconstructive segment. The company also announced the appointment of Damien McDonald as the new CEO, effective May 12, 2025.

Key financial highlights include an 11% year-over-year increase in Reconstructive sales and a 5% rise in Prevention & Recovery sales. Despite a net loss of $56 million from continuing operations, Enovis achieved an adjusted EBITDA of $99 million, reflecting a margin expansion of 160 basis points compared to the previous year.

Looking ahead, Enovis has updated its 2025 financial expectations, projecting revenues between $2.22 billion and $2.25 billion and adjusted EBITDA between $385 million and $395 million. The company remains focused on strategic investments and product launches to drive above-market growth.

Enovis Corporation continues to navigate a complex global environment with a disciplined approach, aiming to maintain its growth trajectory through strategic execution and innovation.